Interestingly, relocalized expression of CYP46A1 in astrocytes has also been reported in several neurological conditions such as after traumatic brain injury [69], in a model of Multiple Sclerosis (MS) [69] and in the brain of patients with Alzheimer’s disease (AD) [70–72], possibly reflecting an adaptive response to altered cholesterol metabolism [71]. This evidence concerns the gene CYP46A1 and myeloid sarcoma.